Publication Name	World Journal of Gastroenterology
Manuscript ID	6334
Country	China

Received	2013-10-14 11:25
Peer-Review Started	2013-10-14 15:16
First Decision by Editorial Office Director
Return for Revision	2014-01-12 13:09
Revised
Publication Fee Transferred
Second Decision by Editor	2014-03-19 13:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-03-19 15:24
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-21 16:03
Publish the Manuscript Online	2014-06-06 16:55

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Wei Wang, Li-Rong Zhao, Xiu-Qiang Lin and Fen Feng
Funding Agency and Grant Number
Corresponding Author	Fen Feng, MD, Department of Gastroenterology, Foshan First People’s Hospital, No. 81 Lingnan Dadaobei, Chancheng District, Foshan 520800, Guangdong Province, China. ffen@fsyyy.com
Key Words	Bevacizumab; Reversible posterior leukoencephalopathy syndrome; Colorectal cancer; Hypertension; Coma
Core Tip	This is the first report of reversible posterior leukoencephalopathy syndrome (RPLS) induced by bevacizumab in China. RPLS is a rare complication of bevacizumab, but may present with life-threatening symptoms such as coma. Sudden blood pressure increase is the most common risk factor, and early recognition and prompt control of blood pressure may make this complication reversible.
Publish Date	2014-06-06 16:55
Citation	Wang W, Zhao LR, Lin XQ, Feng F. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol 2014; 20(21): 6691-6697
URL	http://www.wjgnet.com/1007-9327/full/v20/i21/6691.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i21.6691

Full Article (PDF)	WJG-20-6691.pdf
Full Article (Word)	WJG-20-6691.doc
Manuscript File	6334-Review.doc
Answering Reviewers	6334-Answering Reviewers.pdf
Copyright License Agreement	6334-Copyright Assignment.pdf
Non-Native Speakers of English Editing Certificate	6334-Language certificate.pdf
Peer-review Report	6334-Peer Reviews.pdf
Scientific Editor Work List	6334-Scientific editor work list.doc